Streetbeat News

Revenues

PTVE

Pactiv Evergreen (NASDAQ:PTVE) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for PTVE has been raised to $16.06, indicating a 20.75% increase from the previous target. The company operates in foodservice and food merchandising, facing a revenue decline of -13.69% as of December 31, 2023, but exhibits strong profitability and financial health with exceptional net margin, ROE, and ROA. Its debt-to-equity ratio is below industry average, suggesting a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 7:01 pm

TMO

Thermo Fisher Scientific (NYSE:TMO) has been assessed by 5 analysts over the last three months, showing a mix of bullish to bearish sentiments. Recent evaluations indicate an upward trend in price targets, with an average of $606.4, marking a 12.45% increase from the previous $539.25. The company's financial performance shows a -4.93% decline in revenue growth, but it maintains strong profitability indicators such as a 14.97% net margin and an ROE of 3.54%. Analysts' actions and price target adjustments reflect a positive outlook on TMO's market performance.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 7:00 pm

MS

12 analysts have recently updated their ratings and price targets for Morgan Stanley (NYSE:MS), showing a mix of bullish and indifferent stances with no bearish views. The average 12-month price target is now $97.92, slightly down from $98.90. Analyst actions include both upgrades and downgrades, reflecting a nuanced view of the company's prospects. Morgan Stanley's financial performance shows strong revenue growth and net margin, but challenges in ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 7:00 pm

ELV

Elevance Health (NYSE:ELV) received seven somewhat bullish ratings from analysts, with a current average 12-month price target of $565.57, reflecting a 1.08% increase from the previous target. The company, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, reported a solid revenue growth rate of 6.81% and strong financial metrics including net margin, ROE, and ROA. However, its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:01 pm

NHI

National Health Investors (NHI) has been analyzed by 6 analysts, showing a shift towards a more cautious stance in the last 30 days with an average price target of $64.5, indicating an 11.69% increase from the previous target. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, outperforming industry averages, with a sound debt management strategy.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:01 pm

CMS

CMS Energy (NYSE:CMS) received mixed analyst ratings with a shift towards a more positive outlook, as evidenced by the recent update in price targets and ratings adjustments. The average 12-month price target for CMS has increased to $62.2, reflecting a 1.55% rise from the previous target. Analysts from firms like UBS, Barclays, JP Morgan, and others have made various adjustments to their ratings and price targets, indicating a nuanced view of the company's future performance. Despite facing a revenue decline of -14.4% in the last quarter of 2023, CMS Energy's financial indicators such as net margin, ROE, and ROA remain strong, although its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:01 pm

STT

State Street (NYSE:STT) has been evaluated by 5 analysts over the last three months, showing a shift towards a more positive outlook with an increase in the average 12-month price target from $80.40 to $85.8. Despite this, the majority of analysts remain indifferent, with 4 out of 5 maintaining a neutral stance. The company faces challenges in revenue growth, net margin, ROE, and ROA, lagging behind industry averages, but maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:01 pm

AVTR

Avantor (NYSE:AVTR) has been analyzed by 9 analysts, showing a shift towards a more bullish outlook with recent upgrades in ratings and price targets. The average 12-month price target is now $28.00, marking an 11.73% increase from the previous $25.06. Analysts from firms like Evercore ISI Group, UBS, and Citigroup have raised their price targets, reflecting optimism about Avantor's future performance. Despite this, Avantor faces challenges with a revenue decline of -4.02% and below-average ROE and ROA, indicating potential operational and financial efficiency issues.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:00 pm

UPST

In the past three months, 5 analysts have provided varied ratings for Upstart Holdings (NASDAQ:UPST), with recent actions including maintaining, raising, and lowering ratings and price targets. The average 12-month price target remains at $25.00. Upstart's financials show challenges in revenue growth, profitability, and asset utilization, with a notable decline in revenue by -5.17% as of December 31, 2023, and a net margin of -31.44%. The company's market capitalization and financial performance indicators like ROE and ROA are below industry averages, despite a sound debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:00 pm

TTWO

WBD

Despite the release of new blockbuster games in 2023, older titles like Take-Two Interactive's Grand Theft Auto 5 and Epic Games' Fortnite continue to dominate gaming playtime. A report by Newzoo highlights that 66 games accounted for 80% of playtime, with 60% going to games released six years ago or more. New releases struggled to make an impact, with only a few, including Warner Bros. Discovery's Hogwarts Legacy, making notable achievements.

Portfolio Pulse from Franca Quarneti

April 04, 2024 | 5:54 pm